- Visibility14
- Citations1
- Sentiment50
- Site quality87
- AI readiness29
AI assistants name Merck & Co. in 11.7% of answers, more often than the typical company in its sector. Its overall score is 32 out of 100, ranking 1,045th of 2,047 companies in the study. The company's website passes 4 of 14 technical checks for readiness for AI tools.
We asked 15 unbranded questions about the healthcare market: none named Merck & Co. AI assistants named it in 7 of 60 answers (11.7%). The typical healthcare company is named in 3.3% of answers. By how often it is named, Merck & Co. ranks 20 of 105 in its sector.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
105 companies in this sector. The line on each bar is the typical company.
An answer that names the company
“How does a biopharmaceutical company differ from a traditional pharmaceutical company?”
The fundamental difference between a biopharmaceutical company and a traditional pharmaceutical company lies in their approach to drug development and manufacturing. While both aim to create medicines for various conditions, their methods and the nature of their products differ significantly.
Here's a breakdown of the key distinctions:
Traditional Pharmaceutical Companies
Origin of Products: These companies primarily develop and produce drugs through chemical synthesis in laboratories. Their products are typically made from chemical and plant-based compounds.
Product Exampl …
The AI’s answer as we received it, shortened and not checked for accuracy.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 1: Basic web presence. Two of robots.txt, a sitemap and Link headers are in place.
- Content Signals
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtPassed
A valid robots.txt with crawl rules at the site root.
- study: 86.8%SitemapPassed
An XML sitemap listing the pages, ideally referenced from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtNot met
Publish an llms.txt with a short summary and the key links.
- study: 93.4%AI bot rulesPartly met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 25 of 100 · 97% of checks could run · checked on October 5, 2026 · www.merck.com · 2,047 companies scanned
4 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Passedrobots.txt publishedstudy: 85.0%
- PassedXML sitemapstudy: 73.2%
- PassedHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Not metllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
This website sets no rules for any AI crawler by name, like 84% of the websites whose rules we could read. Every AI crawler follows its general rules.
- GPTBotpartly
- ClaudeBotpartly
- Anthropic-AIpartly
- Google-Extendedpartly
- Applebot-Extendedpartly
- Meta-ExternalAgentpartly
- FacebookBotpartly
- Bytespiderpartly
- CCBotpartly
- Diffbotpartly
- Omgilibotpartly
- OAI-SearchBotpartly
- Claude-SearchBotpartly
- PerplexityBotpartly
- Applebotpartly
- Amazonbotpartly
- YouBotpartly
- ChatGPT-Userpartly
- Claude-Userpartly
- Perplexity-Userpartly
- DuckAssistBotpartly
- MistralAI-Userpartly
Read from the website’s own rules file (robots.txt). An asterisk marks a crawler the file names. The rest follow its general rules. “Partly” means only some pages are blocked.
How many times each website was listed as a source in these answers
In the study as S&P 500.
- Factors that influence the cost of specialty therapies produced by biopharmaceutical companies
- Average price range for newly approved medicines from leading research-driven biopharma companies in the US
- How do large biopharmaceutical firms support patients with complex or rare diseases?
- How does a biopharmaceutical company differ from a traditional pharmaceutical company?
- How can healthcare professionals help patients navigate access to specialty medicines from biopharma companies?
- What are the leading research-intensive biopharmaceutical companies specializing in innovative medicines?
- Is it worth investing in major US-based biopharma companies focused on innovation?
- What are alternative options for patients when access to a specific biopharmaceutical is limited?
- Are research-driven biopharmaceutical firms a good choice for institutional investors looking for long-term growth?
- Non-profit and academic institution options for accessing cutting-edge therapies outside of commercial biopharma companies
- Common issues patients face when enrolling in clinical trials for investigational medicines
- Biologics vs small molecule drug development: pros and cons for healthcare professionals
- Best ways for patients to access new treatments developed by biopharma companies in the US
- Alternatives to traditional biopharmaceutical clinical trial participation for patients seeking emerging therapies
- Best ways for investors to monitor clinical trial pipelines of US-based biopharma companies
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.
A badge of this result that you can show on your own website. Copy the code below.
<a href="https://aeo-audit.rezolve.com/us/merck.com"><img src="https://aeo-audit.rezolve.com/us/badges/merck.com.svg" alt="Overall score 32 of 100, US AI Visibility Study 2026" width="280" height="64"></a>